Acne News and Research RSS Feed - Acne News and Research

Acne is a disorder resulting from the action of hormones and other substances on the skin's oil glands (sebaceous glands) and hair follicles. These factors lead to plugged pores and outbreaks of lesions commonly called pimples or zits. Acne lesions usually occur on the face, neck, back, chest, and shoulders. Although acne is usually not a serious health threat, it can be a source of significant emotional distress. Severe acne can lead to permanent scarring.
Soy isoflavones may help improve metabolic and cardiovascular health in women with PCOS

Soy isoflavones may help improve metabolic and cardiovascular health in women with PCOS

Women who have polycystic ovary syndrome (PCOS)—a common cause of female infertility—may be able to improve their metabolic and cardiovascular health by consuming soy isoflavones, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism. [More]
Scarring can have negative impact on patients' quality of life

Scarring can have negative impact on patients' quality of life

Whether it's from sudden trauma, scheduled surgery or serious acne, scarring can have a profound impact on patients. [More]
Deadly bacteria can travel to the brain and spinal cord in 24 hours, new study finds

Deadly bacteria can travel to the brain and spinal cord in 24 hours, new study finds

A deadly bacteria that can be picked up by a simple sniff can travel to the brain and spinal cord in just 24 hours, a new Griffith University and Bond University study has found. [More]
FDA approves new topical retinoid gel for OTC treatment of acne

FDA approves new topical retinoid gel for OTC treatment of acne

The U.S. Food and Drug Administration today approved Differin Gel 0.1% (adapalene), a once-daily topical gel for the over-the-counter (OTC) treatment of acne. Differin Gel 0.1% is approved for use in people 12 years of age and older. [More]
Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Mallinckrodt plc, a leading global specialty biopharmaceutical company, today announced new retrospective health economic data on H.P. Acthar® Gel (repository corticotropin injection; RCI), which may be an option for the management of multiple sclerosis (MS) relapses. [More]
TAILOR study shows treatment with Erbitux plus FOLFOX improves survival in RAS wild-type mCRC patients

TAILOR study shows treatment with Erbitux plus FOLFOX improves survival in RAS wild-type mCRC patients

Merck, a leading science and technology company, will present data at the ESMO 18th World Congress on Gastrointestinal Cancer from the pivotal Phase III TAILOR study in patients from China, the first prospective trial to evaluate an anti-EGFR antibody in the first-line therapy of patients with RAS wild-type metastatic colorectal cancer (mCRC). [More]
Allergan receives FDA approval to market ACZONE (dapsone) Gel, 7.5% for acne treatment

Allergan receives FDA approval to market ACZONE (dapsone) Gel, 7.5% for acne treatment

Allergan plc, a leading global pharmaceutical company, today announced that the Company has received approval from the U.S. Food and Drug Administration to market ACZONE (dapsone) Gel, 7.5%, a new prescription topical treatment for acne in patients 12 years of age and older. [More]
First patient dosed in Novan's Phase 3 program to evaluate efficacy of SB204 Gel in treatment of acne

First patient dosed in Novan's Phase 3 program to evaluate efficacy of SB204 Gel in treatment of acne

Novan, Inc. today announced that the first patient has been dosed in its Phase 3 program to evaluate the efficacy and safety of its topical nitric oxide product candidate SB204 Gel in the treatment of acne vulgaris ("acne"). The Company is running two identically designed Phase 3 pivotal trials in parallel and expects to report top-line results in the first half of 2017. [More]
Early strength training could help prevent ACL injuries in young women

Early strength training could help prevent ACL injuries in young women

Young women demonstrate less strength and neuromuscular control after puberty, and this may make them particularly susceptible to Anterior Cruciate Ligament (ACL) injuries, according to research presented this week at the Association of Academic Physiatrists Annual Meeting in Sacramento, Calif. [More]
Perrigo closes previously announced acquisition of generic Retin-A portfolio from Matawan Pharmaceuticals

Perrigo closes previously announced acquisition of generic Retin-A portfolio from Matawan Pharmaceuticals

Perrigo Company plc announced today that it has completed the previously announced acquisition of a portfolio of generic dosage forms and strengths of Retin-A (tretinoin) from Matawan Pharmaceuticals, LLC. [More]

Perrigo to acquire generic Retin-A portfolio from Matawan Pharmaceuticals

Perrigo Company plc announced today that it will acquire a portfolio of generic dosage forms and strengths of Retin-A (tretinoin) from Matawan Pharmaceuticals, LLC. Perrigo was the authorized generic distributor of these products from 2005 to 2013 before the agreement was terminated. [More]
Women with moderate-to-severe PMS at increased risk of developing high blood pressure in later life

Women with moderate-to-severe PMS at increased risk of developing high blood pressure in later life

In the first prospective study to consider premenstrual syndrome (PMS) as a possible sentinel for future risk of hypertension, epidemiologist Elizabeth Bertone-Johnson and colleagues in the School of Public Health and Health Sciences at the University of Massachusetts Amherst and the Harvard School of Public Health report that women with moderate-to-severe PMS had a 40 percent higher risk of developing high blood pressure over the following 20 years compared to women experiencing few menstrual symptoms. [More]

Syneron Medical reports revenue of $62.1 million for third quarter 2015

Syneron Medical Ltd., a leading global aesthetic device company, today announced financial results for the three month period ended September 30, 2015. [More]
LEO Pharma enters into Asset Purchase Agreement to acquire Astellas’ global dermatology business

LEO Pharma enters into Asset Purchase Agreement to acquire Astellas’ global dermatology business

LEO Pharma A/S, a global healthcare company dedicated to helping people achieve healthy skin, and Japanese pharmaceutical company Astellas Pharma Inc. today announced that they have entered into an Asset Purchase Agreement under which Astellas will transfer its global dermatology business to LEO Pharma for € 675 million. [More]
Paratek initiates Omadacycline phase 3 clinical study in community acquired bacterial pneumonia (CABP)

Paratek initiates Omadacycline phase 3 clinical study in community acquired bacterial pneumonia (CABP)

Paratek Pharmaceuticals, Inc. has announced the dosing of the first patient in its Phase 3 clinical study of its lead drug candidate, omadacycline, for the treatment of Community Acquired Bacterial Pneumonia (CABP). This global Phase 3 study will assess the efficacy and safety of omadacycline compared with moxifloxacin in subjects with CABP. [More]
Physicians leave severe acne patients on ineffective antibiotics for too long before prescribing more potent drug

Physicians leave severe acne patients on ineffective antibiotics for too long before prescribing more potent drug

A medical records analysis by researchers at NYU Langone Medical Center concludes that physicians who treat severe acne leave too many patients on ineffective antibiotics for far too long before prescribing more potent needed therapy with the medication isotretinoin, sometimes known by its former brand name Accutane. [More]
Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Mallinckrodt plc, a leading specialty biopharmaceutical company, today announced that data from a pilot study for its H.P. Acthar Gel (repository corticotropin injection) will be presented at the American College of Rheumatology 2015 Annual Meeting to be held November 7-11 in San Francisco. [More]
Survey: One-third of US women use compounded hormones at menopause

Survey: One-third of US women use compounded hormones at menopause

A third of US women who take hormones at menopause are using compounded hormones, shows a new national survey. These women commonly--and mistakenly--think these hormones are safer and offer more benefits than FDA-approved therapies. [More]
GIOTRIF shows superior survival compared to Tarceva for patients previously treated with advanced squamous cell lung carcinoma

GIOTRIF shows superior survival compared to Tarceva for patients previously treated with advanced squamous cell lung carcinoma

Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, new data from the Phase III LUX-Lung 8 trial which further highlights the benefits of afatinib compared to erlotinib for the treatment of patients with previously treated advanced SCC of the lung [More]
Weight loss and exercise improve ovulation in women with polycystic ovary syndrome

Weight loss and exercise improve ovulation in women with polycystic ovary syndrome

Weight loss and exercise improve ovulation in women who have polycystic ovary syndrome, a common hormone disorder that often causes infertility, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism. [More]
Advertisement